TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Cipher Pharmaceuticals ( (TSE:CPH) ).
Cipher Pharmaceuticals announced it will release its financial results for the second quarter of 2025 on August 7, followed by a conference call on August 8 to discuss the results and corporate developments. This announcement highlights the company’s ongoing commitment to transparency and communication with stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (TSE:CPH) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Cipher Pharmaceuticals stock, see the TSE:CPH Stock Forecast page.
Spark’s Take on TSE:CPH Stock
According to Spark, TipRanks’ AI Analyst, TSE:CPH is a Outperform.
Cipher Pharmaceuticals is positioned well with strong revenue growth and strategic initiatives, particularly the Natroba acquisition and debt management. However, technical analysis indicates potential short-term weakness, and profitability challenges persist.
To see Spark’s full report on TSE:CPH stock, click here.
More about Cipher Pharmaceuticals
Cipher Pharmaceuticals is a specialty pharmaceutical company with a diverse portfolio of commercial and developmental products primarily in dermatology. The company focuses on acquiring products that address unmet medical needs and oversees their clinical development and regulatory approval, marketing these products in Canada, the U.S., and South America.
Average Trading Volume: 21,411
Technical Sentiment Signal: Buy
Current Market Cap: C$323.9M
See more insights into CPH stock on TipRanks’ Stock Analysis page.